Tallinn, Estonia

Innomedica OU

Ulcerative Colitis

Colitis

Ulcer

Psoriatic Arthritis

Meningitis

Human Influenza

Meningococcal Meningitis

Arthritis

Psoriasis

CP-690,550

Zasocitinib

PF-06700841

Pfizer

Alvotech

Moderna

Takeda

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.

The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.

Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).

Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Innomedica OU | Tallinn, Estonia

Site insights

Work at this site?

Active trials

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Trial sponsors